Ispire Q1 Revenue $27.5M, Adjusted EBITDA Back to Positive

Ispire Technology Inc. (Nasdaq: ISPR) reported first quarter fiscal 2027 results on 9 November 2026, posting revenue of $27.5 million and a net loss of $6.4 million, or $0.11 per share. Gross margin recovered to 16.2% from 6.3% in the prior quarter, and Adjusted EBITDA turned positive at $136,000, a $2.4 million sequential improvement. Revenue rose 3.2% from $26.7 million in the fourth quarter of fiscal 2026 but fell 9.3% from $30.4 million a year earlier.

Context — Why Ispire's Margin Recovery Matters Now

The company's fourth quarter of fiscal 2026 included one-time inventory impairments and returns charges that crushed gross margin to 6.3%. Those charges did not repeat at the same scale, and the sequential recovery to 16.2% shows the underlying cost structure held. That is the single most important number in the release, because it separates a one-off accounting event from a durable operating problem.

Revenue direction is less encouraging. The 9.3% year-over-year decline came primarily from reduced European sales, which the company attributed to an increasingly restrictive regulatory environment for vaping products. Europe has been a growth market for vapor hardware, so a regulatory-driven pullback there removes a leg of the demand story.

The sequential uptick of 3.2% suggests the worst of the European contraction may have already been booked, though one quarter is not a trend.

Operating expenses rose 35.2% year over year to $10.6 million, driven mostly by non-cash credit loss expenses of $4.8 million. Sequentially, total operating expenses fell 30.4% from $15.2 million. The company also said it reduced net accounts receivable by roughly 80% from peak fiscal 2025 levels, achieved through collections, allowances for credit losses and tighter customer credit standards.

Management framed the quarter around diversification: Malaysia manufacturing, a growing Vapor OEM and ODM pipeline, G-Mesh technology, its 40% owned joint venture IKE Tech and a nicotine pouch joint venture with Jincheng Pharma.

Data — What the Numbers Show

The headline figures compare cleanly across three periods. Revenue of $27.5 million sits between the $30.4 million recorded a year ago and the $26.7 million booked last quarter. Gross profit of $4.5 million compares with $5.1 million a year ago, so the margin gain is a rate story, not a dollar story.

Metric	Q1 FY2027	Q4 FY2026	Q1 FY2026
Revenue	$27.5M	$26.7M	$30.4M
Gross margin	16.2%	6.3%	17.0%
Net loss	$6.4M	$13.8M	$3.3M
Adjusted EBITDA	$136K	($2.3M)	$0.6M
Credit loss expense	$4.8M	$9.2M	$1.8M

Credit loss expense of $4.8 million is the swing factor. It rose $3.0 million year over year and accounted for roughly three-quarters of the quarterly net loss. Strip it out, along with stock-based compensation of $817,323, income tax expense of $336,637, inventory impairment of $418,500 and depreciation and amortization of $216,811, and the business produced positive Adjusted EBITDA.

Balance sheet pressure is visible. Cash fell $3.7 million to $15.6 million from $19.3 million at fiscal year end. Working capital dropped $0.4 million to just $0.4 million. Total stockholders' deficit widened to $34.8 million from $29.2 million, and the amount due to a related party rose $5.0 million to $52.0 million.

Accounts receivable, net, fell to $13.5 million from $19.8 million. Inventories, net, declined to $2.6 million from $3.1 million. Accounts payable and related-party payables together fell by roughly $9.3 million.

Analysis — What It Means for ISPR Holders

Ispire sits in a niche where regulatory risk is the dominant variable. The company's own explanation for the revenue decline points to European vaping restrictions, which means the top line is exposed to policy decisions the company does not control. Any investor modeling ISPR growth has to underwrite that regulatory path, not just execution.

The credit loss line is the second-order effect worth watching. A $4.8 million charge against a $27.5 million revenue base is unusually large for a hardware manufacturer, and it implies customers struggled to pay. The company's response — tighter credit standards and shorter payment terms — should reduce future losses but also risks slowing order flow if buyers push back.

Liquidity is the counter-argument to the recovery narrative. Working capital of $0.4 million and cash of $15.6 million against a $52.0 million related-party payable is a thin cushion. If credit losses persist at current levels, the company's stated goal of cash-flow-positive performance becomes harder to reach without external funding.

Management's Malaysia build-out is a capital commitment running in the opposite direction, and the company said it expects cash flow to improve only as new manufacturing and commercial programs begin to scale.

Positioning is difficult to read from the release alone. The company flagged a potential OEM and ODM relationship with a well-known Southeast Asian brand but did not name the counterparty, disclose terms or commit to a timeline beyond "the coming months." IKE Tech's planned U.S. pilot of its IKE 2.0 age-gating platform with Charlie's Holdings is similarly early-stage.

Outlook — What to Watch Next

The company's stated priority is reaching cash-flow-positive performance while funding Malaysia. Investors should watch the credit loss line in the next quarter; a second consecutive $4 million-plus charge would suggest the receivable problem is structural rather than a collections lag.

Gross margin is the second marker. Holding above the 16.2% level would confirm the fourth-quarter impairments were genuinely one-time. A slide back toward single digits would undermine the recovery case.

Management said it is close to securing a significant OEM and ODM relationship with a regional Southeast Asian brand and hopes to update investors in the coming months. The company did not disclose the identity of the counterparty or the expected contract value.

A conference call was scheduled for 8 a.m. ET on 9 November 2026, with a replay available until 23 November 2026.

Frequently Asked Questions

Why did Ispire's net loss widen year over year?

Net loss widened to $6.4 million from $3.3 million a year earlier even though gross margin held near prior levels. The driver was credit loss expense of $4.8 million, up $3.0 million year over year, plus a 35.2% rise in total operating expenses. Sales and marketing spending actually fell to $1.0 million from $1.6 million, so the increase was concentrated in credit losses and general and administrative costs.

What is driving Ispire's European revenue decline?

The company attributed the 9.3% year-over-year revenue drop primarily to reduced European sales amid what it described as an increasingly restrictive regulatory environment for vaping products. Ispire did not break out European revenue as a separate line item, so the precise magnitude of the regional decline is not disclosed. The company's branded Aspire products are sold worldwide except in the U.S., China and Russia.

How much cash does Ispire have left?

Ispire held $15.6 million in cash at 30 September 2026, down $3.7 million from $19.3 million at the fiscal year ended 30 June 2026. Working capital stood at $0.4 million. The company also carries a $52.0 million amount due to a related party on the non-current side of the balance sheet, up from $47.0 million at fiscal year end.

Bottom Line

Ispire's margin recovery and return to positive Adjusted EBITDA are real, but a $4.8 million credit loss charge and $0.4 million working capital leave little room for error.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.